TY - JOUR
T1 - Clinical characteristics of Japanese pustular psoriasis
T2 - A multicenter observational study
AU - Western Japan Inflammatory Disease Research Group
AU - Ohata, Chika
AU - Tsuruta, Noriko
AU - Yonekura, Kentaro
AU - Higashi, Yuko
AU - Saito, Kanami
AU - Katayama, Eri
AU - Imafuku, Shinichi
AU - Ohata, Chika
AU - Tsuruta, Noriko
AU - Kaneko, Sakae
AU - Ito, Kotaro
AU - Matsuzaka, Yuki
AU - Koike, Yuta
AU - Murota, Hiroyuki
AU - Miyagi, Takuya
AU - Sakugawa, Hiroyuki
AU - Takahashi, Kenzo
AU - Okazaki, Fusako
AU - Yamaguchi, Kazuki
AU - Sugita, Kazunari
AU - Hashimoto, Aki
AU - Kuwashiro, Maki
AU - Yonekura, Kentaro
AU - Okada, Etsuko
AU - Sasaki, Natsuko
AU - Higashi, Yuko
AU - Furue, Masutaka
AU - Nakahara, Takeshi
AU - Ikeda, Kenta
AU - Morizane, Shin
AU - Hatano, Yutaka
AU - Saito, Kanami
AU - Kikuchi, Satoko
AU - Harada, Kayo
AU - Katayama, Eri
AU - Ohyama, Bungo
AU - Imafuku, Shinichi
N1 - Funding Information:
The WJPR is run by a non‐profit organization, the Western Japan Inflammatory Skin Disease Research Group, and is supported by precious funding support from the Japanese Society for Psoriasis Research, Amgen, Abbvie, Eisai, Taiho Yakuhin Kogyo, Kyowa Kirin, Maruho, and Sun pharma.
Publisher Copyright:
© 2021 Japanese Dermatological Association
PY - 2022/1
Y1 - 2022/1
N2 - Generalized pustular psoriasis (GPP) is a rare and severe subtype of psoriasis. Because of its rarity, GPP studies with a large sample size have been scarce. We studied the characteristics of GPP and pustular psoriasis using data from the West Japan Psoriasis Registry that had been registered until the end of December 2020. The dataset included 104 patients with pustular psoriasis and 1290 patients with other subtypes of psoriasis. Multivariate analysis revealed a significantly greater number of female patients, a significantly lower mean body mass index, and a significantly lower ratio of habitual drinkers in pustular psoriasis, compared to other subtypes of psoriasis. Of the 104 patients, 102 had GPP, including 88 von Zumbusch, 10 juvenile-onset, and four annular pustular psoriasis. Although the male : female ratio of GPP with psoriasis vulgaris (GPP+PsV) (47/20) was similar to that of psoriasis in Japan, the GPP without PsV (GPP−PsV) group highlighted a female predominance (13/22). The mean age at GPP onset was 45.3 years, and the mean interval from PsV onset to GPP onset was 12.5 years. Four of nine patients with GPP had an IL36RN gene mutation. Infection, medicine, and pregnancy were the precipitating factors for GPP. A family history of psoriasis was present in eight (7.8%) patients with GPP. Twenty-four patients with GPP had psoriatic arthritis. Biologics were used in 76.5% of patients with GPP, followed by etretinate (37.3%), cyclosporine (24.5%), methotrexate (13.7%), apremilast (8.8%), and granulocyte and monocyte adsorption apheresis (6.9%). Etretinate was used in 17 (51.5%) of 33 patients with GPP with less than 10-year history. Thus, etretinate remains a good treatment option for GPP even in the era of biologics. Hypertension was the most commonly identified comorbidity, followed by diabetes. We believe that the characteristics revealed in this study can further contribute to effective GPP management.
AB - Generalized pustular psoriasis (GPP) is a rare and severe subtype of psoriasis. Because of its rarity, GPP studies with a large sample size have been scarce. We studied the characteristics of GPP and pustular psoriasis using data from the West Japan Psoriasis Registry that had been registered until the end of December 2020. The dataset included 104 patients with pustular psoriasis and 1290 patients with other subtypes of psoriasis. Multivariate analysis revealed a significantly greater number of female patients, a significantly lower mean body mass index, and a significantly lower ratio of habitual drinkers in pustular psoriasis, compared to other subtypes of psoriasis. Of the 104 patients, 102 had GPP, including 88 von Zumbusch, 10 juvenile-onset, and four annular pustular psoriasis. Although the male : female ratio of GPP with psoriasis vulgaris (GPP+PsV) (47/20) was similar to that of psoriasis in Japan, the GPP without PsV (GPP−PsV) group highlighted a female predominance (13/22). The mean age at GPP onset was 45.3 years, and the mean interval from PsV onset to GPP onset was 12.5 years. Four of nine patients with GPP had an IL36RN gene mutation. Infection, medicine, and pregnancy were the precipitating factors for GPP. A family history of psoriasis was present in eight (7.8%) patients with GPP. Twenty-four patients with GPP had psoriatic arthritis. Biologics were used in 76.5% of patients with GPP, followed by etretinate (37.3%), cyclosporine (24.5%), methotrexate (13.7%), apremilast (8.8%), and granulocyte and monocyte adsorption apheresis (6.9%). Etretinate was used in 17 (51.5%) of 33 patients with GPP with less than 10-year history. Thus, etretinate remains a good treatment option for GPP even in the era of biologics. Hypertension was the most commonly identified comorbidity, followed by diabetes. We believe that the characteristics revealed in this study can further contribute to effective GPP management.
KW - biologics
KW - body mass index
KW - comorbidity
KW - generalized pustular psoriasis
KW - pustular psoriasis
UR - http://www.scopus.com/inward/record.url?scp=85123234303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123234303&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.16217
DO - 10.1111/1346-8138.16217
M3 - Article
C2 - 34723399
AN - SCOPUS:85123234303
SN - 0385-2407
VL - 49
SP - 142
EP - 150
JO - Journal of Dermatology
JF - Journal of Dermatology
IS - 1
ER -